By Adjunct Professor Michael Leonard Friedlander

Journal articles

Kok PS; Beale P; O’Connell RL; Grant P; Bonaventura T; Scurry J; Antill Y; Goh J; Sjoquist K; Defazio A; Mapagu C; Amant F; Friedlander M, 2019, 'PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression', Journal of Gynecologic Oncology, 30, http://dx.doi.org/10.3802/jgo.2019.30.e86

Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M, 2019, 'PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors', Gynecologic Oncology, 154, pp. 531 - 538, http://dx.doi.org/10.1016/j.ygyno.2019.06.011

Lee CK; Asher R; Friedlander M; Gebski V; Gonzalez-Martin A; Lortholary A; Lesoin A; Kurzeder C; Largillier R; Hilpert F; Hardy-Bessard AC; Kaminsky MC; Poveda A; Pujade-Lauraine E, 2019, 'Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy', European Journal of Cancer, 117, pp. 99 - 106, http://dx.doi.org/10.1016/j.ejca.2019.05.029

Zeinomar N; Phillips KA; Daly MB; Milne RL; Dite GS; MacInnis RJ; Liao Y; Kehm RD; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; John EM; Hopper JL; Terry MB, 2019, 'Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort', International Journal of Cancer, 145, pp. 370 - 379, http://dx.doi.org/10.1002/ijc.32112

Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M, 2019, 'Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903', Gynecologic Oncology, 154, pp. 29 - 37, http://dx.doi.org/10.1016/j.ygyno.2019.05.007

Kehm RD; Hopper JL; John EM; Phillips KA; MacInnis RJ; Dite GS; Milne RL; Liao Y; Zeinomar N; Knight JA; Southey MC; Vahdat L; Kornhauser N; Cigler T; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; Terry MB, 2019, 'Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1135-y

Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ, 2019, '10-year performance of four models of breast cancer risk: a validation study', Lancet Oncology, 20, pp. 504 - 517, http://dx.doi.org/10.1016/S1470-2045(18)30902-1

Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK, 2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278, http://dx.doi.org/10.1007/s10549-018-5054-x

Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M, 2019, 'Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer', British Journal of Cancer, 120, pp. 279 - 285, http://dx.doi.org/10.1038/s41416-018-0349-6

Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer', Obstetrical and Gynecological Survey, 74, pp. 86 - 87, http://dx.doi.org/10.1097/01.ogx.0000552695.03241.d6

Rose PG; Java JJ; Salani R; Geller MA; Secord AA; Tewari KS; Bender DP; Mutch DG; Friedlander ML; Van Le L; Method MW; Hamilton CA; Lee RB; Wenham RM; Guntupalli SR; Markman M; Muggia FM; Armstrong DK; Bookman MA; Burger RA; Copeland LJ, 2019, 'Nomogram for Predicting Individual Survival after Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma', Obstetrics and Gynecology, 133, pp. 245 - 254, http://dx.doi.org/10.1097/AOG.0000000000003086

Mavaddat N; Michailidou K; Dennis J; Lush M; Fachal L; Lee A; Tyrer JP; Chen TH; Wang Q; Bolla MK; Yang X; Adank MA; Ahearn T; Aittomäki K; Allen J; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Auer PL; Auvinen P; Barrdahl M; Beane Freeman LE; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bernstein L; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Børresen-Dale AL; Brauch H; Bremer M; Brenner H; Brentnall A; Brock IW; Brooks-Wilson A; Brucker SY; Brüning T; Burwinkel B; Campa D; Carter BD; Castelao JE; Chanock SJ; Chlebowski R; Christiansen H; Clarke CL; Collée JM; Cordina-Duverger E; Cornelissen S; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dumont M; Durcan L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Ellberg C; Engel C; Eriksson M; Evans DG; Fasching PA; Figueroa J; Fletcher O; Flyger H; Försti A; Fritschi L; Gabrielson M; Gago-Dominguez M; Gapstur SM; García-Sáenz JA; Gaudet MM; Georgoulias V; Giles GG; Gilyazova IR; Glendon G; Goldberg MS; Goldgar DE; González-Neira A; Grenaker Alnæs GI; Grip M; Gronwald J; Grundy A; Guénel P; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hamann U; Hankinson SE, 2019, 'Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes', American Journal of Human Genetics, 104, pp. 21 - 34, http://dx.doi.org/10.1016/j.ajhg.2018.11.002

McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB, 2019, 'Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments', Jnccn Journal of the National Comprehensive Cancer Network, 17, pp. 949 - 955, http://dx.doi.org/10.6004/jnccn.2019.7290

Kee D; Parker C; Bae S; Tucker KM; Harrison M; Tohidi-Esfahani I; Black M; Delahunty R; Ananda S; Friedlander M; Cunliffe HE; Gibbs P; Desai J; Trotman J; Scott CL, 2019, 'CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research', JCO Clinical Cancer Informatics, 3, pp. 136 - 146, http://dx.doi.org/10.1200/CCI.19.00085

Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2019, 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))', Gynecologic Oncology, 152, pp. 220, http://dx.doi.org/10.1016/j.ygyno.2018.10.022

Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Arnau GM; Okamoto A; Friedlander M; Bowtell DDL, 2019, 'Survival following chemotherapy in ovarian clear cell carcinoma is not associated with pathological misclassification of tumor histotype', Clinical Cancer Research, 25, pp. 3962 - 3973, http://dx.doi.org/10.1158/1078-0432.CCR-18-3691

Friedlander ML; Hettle R; Parkhomenko E, 2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', Annals of Oncology, 30, pp. ix77 - ix78, http://dx.doi.org/10.1093/annonc/mdz426.001

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; DiSilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', Annals of Oncology, 30, pp. v405 - v406, http://dx.doi.org/10.1093/annonc/mdz250.004

Diéras VC; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Dudley M; Ratajczak CK; Maag D; Arun BK, 2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', Annals of Oncology, 30, pp. v857 - v858, http://dx.doi.org/10.1093/annonc/mdz394.008

Oaknin A; Moore K; Colombo N; Scambia G; Kim B-G; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', Annals of Oncology, 30, pp. v405 - v405, http://dx.doi.org/10.1093/annonc/mdz250.003

Antill Y; Kok PS; Stockler MR; Robledo K; Yip S; Parry M; Smith D; Spurdle A; Barnes E; Friedlander ML; Baron-Hay S; Shannon C; Coward J; Beale PJ; Goss G; Meniawy T; Andrews J; Kelly M; Mileshkin L, 2019, 'Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)', Annals of Oncology, 30, pp. ix192 - ix192, http://dx.doi.org/10.1093/annonc/mdz446.011

Kok PS; Yoon W-H; Marschner I; Lord SJ; Friedlander M; Lee CK, 2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', Annals of Oncology, 30, pp. v520 - v520, http://dx.doi.org/10.1093/annonc/mdz253.103

Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', Annals of Oncology, 30, pp. v895 - v896, http://dx.doi.org/10.1093/annonc/mdz394.054

Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer', New England Journal of Medicine, 379, pp. 2495 - 2505, http://dx.doi.org/10.1056/NEJMoa1810858

Beesley VL; Smith DD; Nagle CM; Friedlander M; Grant P; DeFazio A; Webb PM, 2018, 'Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer', Supportive Care in Cancer, 26, pp. 4133 - 4142, http://dx.doi.org/10.1007/s00520-018-4284-0

Joo JE; Dowty JG; Milne RL; Wong EM; Dugué PA; English D; Hopper JL; Goldgar DE; Giles GG; Southey MC; Sexton A; Christian A; Trainer A; Spigelman A; Fellows A; Shelling A; De Fazio A; Blackburn A; Crook A; Meiser B; Patterson B; Clarke C; Saunders C; Hunt C; Scott C; Amor D; Marsh D; Edkins E; Salisbury E; Haan E; Neidermayr E; Macrae F; Farshid G; Lindeman G; Chenevix-Trench G; Mann G; Gill G; Thorne H; Campbell I; Hickie I; Winship I; Goldblatt J; Flanagan J; Kollias J; Visvader J; Stone J; Taylor J; Burke J; Saunus J; Forbes J; Beesley J; Kirk J; French J; Tucker K; Wu K; Phillips K; Lipton L; Andrews L; Lobb E; Walker L; Kentwell M; Spurdle A; Cummings M; Gleeson M; Harris M; Jenkins M; Young MA; Delatycki M; Wallis M; Burgess M; Price M; Brown M; Bogwitz M; Field M; Friedlander M; Gattas M; Saleh M; Hayward N; Pachter N; Cohen P; Duijf P; James P; Simpson P; Fong P; Butow P; Williams R; Kefford R; Scott R; Balleine R; Dawson SJ; Lok S; O'Connell S; Greening S; Nightingale S; Edwards S; Fox S; McLachlan SA; Lakhani S; Thomas S; Antill Y, 2018, 'Heritable DNA methylation marks associated with susceptibility to breast cancer /631/67/69 /631/337/176/1988 /692/699/67/1347 /692/308/2056 /45 /45/61 article', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-03058-6

Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; Chenevix-Trench G; Green A; Webb P; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J, 2018, 'Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-05564-z

Friedlander M; Shannon C; Goh J; Scott C; Mileshkin L, 2018, 'Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib', Asia Pacific Journal of Clinical Oncology, 14, pp. 459 - 464, http://dx.doi.org/10.1111/ajco.13104

Hopper JL; Dite GS; MacInnis RJ; Liao Y; Zeinomar N; Knight JA; Southey MC; Milne RL; Chung WK; Giles GG; Genkinger JM; McLachlan SA; Friedlander ML; Antoniou AC; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; John EM; Phillips KA; Terry MB, 2018, 'Age-specific breast cancer risk by body mass index and familial risk: Prospective family study cohort (ProF-SC)', Breast Cancer Research, 20, http://dx.doi.org/10.1186/s13058-018-1056-1

Friedlander M; Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; Disilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. ix174 - ix175, http://dx.doi.org/10.1093/annonc/mdy483.002

Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J, 2018, 'Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy', British Journal of Cancer, 119, pp. 1075 - 1085, http://dx.doi.org/10.1038/s41416-018-0271-y

Berek JS; Kehoe ST; Kumar L; Friedlander M, 2018, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 143, pp. 59 - 78, http://dx.doi.org/10.1002/ijgo.12614

Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2018, 'Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study', Gynecologic Oncology, 151, pp. 18 - 23, http://dx.doi.org/10.1016/j.ygyno.2018.07.021

Terry MB; Liao Y; Kast K; Antoniou AC; McDonald JA; Mooij TM; Engel C; Nogues C; Buecher B; Mari V; Moretta-Serra J; Gladieff L; Luporsi E; Barrowdale D; Frost D; Henderson A; Brewer C; Evans DG; Eccles D; Cook J; Ong KR; Izatt L; Ahmed M; Morrison PJ; Dommering CJ; Oosterwijk JC; Ausems MGEM; Kriege M; Buys SS; Andrulis IL; John EM; Daly M; Friedlander M; McLachlan SA; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; van Leeuwen FE; Goldgar D; Milne RL; Easton DF; Rookus MA; Andrieu N, 2018, 'The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations', Jnci Cancer Spectrum, 2, http://dx.doi.org/10.1093/JNCICS/PKY078

Wilson MK; Mercieca-Bebber R; Friedlander M, 2018, 'A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer', Journal of Gynecologic Oncology, 29, http://dx.doi.org/10.3802/jgo.2018.29.e81

Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML, 2018, 'Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials', Gynecologic Oncology, 150, pp. 527 - 533, http://dx.doi.org/10.1016/j.ygyno.2018.07.013

Friedlander M; Gebski V; Gibbs E; Davies L; Bloomfield R; Hilpert F; Wenzel LB; Eek D; Rodrigues M; Clamp A; Penson RT; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Espinoza D; Joly F; Pujade-Lauraine E, 2018, 'Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial', Lancet Oncology, 19, pp. 1126 - 1134, http://dx.doi.org/10.1016/S1470-2045(18)30343-7

Loo CKC; Danieletto S; Friedlander M; Pearen MA; Ramm GA, 2018, 'Peritoneal hepatoid carcinoma with chemotherapy response and possible stem cell involvement', Human Pathology Case Reports, 12, pp. 71 - 76, http://dx.doi.org/10.1016/j.ehpc.2018.02.008

Grimison PS; Lawrence NJ; Stockler MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; McDermott R; Walker R; Winstanley M; Hanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC, 2018, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).', Journal of Clinical Oncology, 36, pp. TPS4596 - TPS4596, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.tps4596

Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK, 2018, 'Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis', JAMA Oncology, 4, pp. 522 - 528, http://dx.doi.org/10.1001/jamaoncol.2017.5236

Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J, 2018, 'Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries', Annals of Oncology, 29, pp. 910 - 916, http://dx.doi.org/10.1093/annonc/mdy037

Schrijver LH; Olsson H; Phillips KA; Terry MB; Goldgar DE; Kast K; Engel C; Mooij TM; Adlard J; Barrowdale D; Davidson R; Eeles R; Ellis S; Evans DG; Frost D; Izatt L; Porteous ME; Side LE; Walker L; Berthet P; Bonadona V; Leroux D; Mouret-Fourme E; Venat-Bouvet L; Buys SS; Southey MC; John EM; Chung WK; Daly MB; Bane A; van Asperen CJ; Garcia EBG; Mourits MJE; Roos-Blom MJ; Friedlander ML; McLachlan SA; Singer CF; Foretova L; Gerdes AM; Caldes T; Olah E; Jakubowska A; Noguès C; Andrieu N; Easton DF; van Leeuwen FE; Hopper JL; Milne RL; Antoniou AC; Rookus MA; Laborde L; Pontois P; Stoppa-Lyonnet D; Gauthier-Villars M; Buecher B; Caron O; Fricker JP; Lasset C; Faivre L; Luporsi E; Frénay M; Gladieff L; Gesta P; Sobol H; Eisinger F; Moretta J; Longy M; Dugast C; Colas C; Soubrier F; Coupier I; Pujol P; Lortholary A; Vennin P; Adenis C; Nguyen TD; Delnatte C; Rossi A; Tinat J; Tennevet I; Limacher JM; Maugard C; Bignon YJ; Demange L; Dreyfus H; Cohen-Haguenauer O; Gilbert B; Zattara-Cannoni H, 2018, 'Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study', Jnci Cancer Spectrum, 2, http://dx.doi.org/10.1093/jncics/pky023

Sousa M; Peate M; Lewis C; Jarvis S; Willis A; Hickey M; Friedlander M, 2018, 'Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy', European Journal of Cancer Care, 27, http://dx.doi.org/10.1111/ecc.12820

Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Toloczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubinski J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Glaz A; Chenevix-Trench G; Cazorla A; Brucker SY; Bowtell DD; Green A; Webb P; de Fazio A; Gertig D; Moore S; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R, 2018, 'MyD88 and TLR4 Expression in Epithelial Ovarian Cancer', Mayo Clinic Proceedings, 93, pp. 307 - 320, http://dx.doi.org/10.1016/j.mayocp.2017.10.023

Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A, 2018, 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy', Annals of Oncology, 29, pp. 737 - 743, http://dx.doi.org/10.1093/annonc/mdx796

Wilson MK; Friedlander ML; Joly F; Oza AM, 2018, 'A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve', Oncologist, 23, pp. 203 - 213, http://dx.doi.org/10.1634/theoncologist.2017-0297

Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Gares V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart C; Sharma R; Allan PE; Rambau PF; Traficante N; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Kobel M; Harnett P; Nelson BH; Bowtell DDL; DeFazio A, 2018, 'Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer', Clinical Cancer Research, 24, pp. 569 - 580, http://dx.doi.org/10.1158/1078-0432.CCR-17-1621

Friedlander M; van Rijn J, 2018, 'Ammonia and CO₂ enrichment of a Gracilaria cultivation pond through biofiltration of organic waste', AQUACULTURE, 482, pp. 45 - 48, http://dx.doi.org/10.1016/j.aquaculture.2017.08.041

Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M, 2018, 'Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients', Gynecologic Oncology, 148, pp. 79 - 85, http://dx.doi.org/10.1016/j.ygyno.2017.10.036

King MT; Stockler MR; O’Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML, 2018, 'Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer', Quality of Life Research, 27, pp. 59 - 74, http://dx.doi.org/10.1007/s11136-017-1729-8

Back to profile page